Genome-wide de novo methylation in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 21, Issue 2, 2011, Pages 269-279

  Michaelson Cohen, Rachel ^a   Keshet, Ilana ^a   Straussman, Ravid ^a   Hecht, Merav ^a   Cedar, Howard ^a   Beller, Uziel ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Biomarkers; Gene methylation; Ovarian cancer

Indexed keywords

5 METHYLCYTOSINE; ANTIBODY; BIOLOGICAL MARKER; BISULFITE;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CPG ISLAND; DNA HYBRIDIZATION; DNA METHYLATION; FEMALE; GENE IDENTIFICATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH; UNINDEXED SEQUENCE;

CPG ISLANDS; DNA METHYLATION; GENE SILENCING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 79956112921     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31820e5cda     Document Type: Article

References (32)

1. Keshet I, Schlesinger Y, Cedar H, et al. Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 2006;38:149-153. (Pubitemid 43177227)
2. Cedar H. DNA methylation and gene activity. Cell. 1988;53: 3-4.
3. Siegfried Z, Eden S, Cedar H, et al. DNA methylation represses transcription in vivo. Nat Genet. 1999;22:203-206. (Pubitemid 29264820)
4. Razin A. CpG methylation, chromatin structure and gene silencing-a three-way connection. EMBO J. 1998;17: 4905-4908. (Pubitemid 28408457)
5. Schlesinger Y, Straussman R, Cedar H, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39:232-236. (Pubitemid 46184355)
6. Baylin S, Bestor T. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell. 2002;1:299-305. (Pubitemid 41039130)
7. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet. 2007;8:9-22. (Pubitemid 46006046)
8. Nephew KP, Huang TH. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 2003;190:125-133. (Pubitemid 36136010)
9. Feldman N, Gerson A, Fang J, et al. G9a mediated irreversible epigenetic activation of Oct- 3/4 during early embryogenesis. Nat Cell Biol. 2006;8:188-194.
10. Plath K, Fang J, Mlynarczyk-Evans SK, et al. Role of histone H3 lysine 27 methylation in X inactivation. Science. 2003; 300:131-135. (Pubitemid 36423045)
11. Silva J, Winifred Mak, Ilona Zvetkova, et al. Establishment of histone H3 methylation on the inactive X chromosome requires transient recruitment of Eed-Enx 1 polycomb group complexes. Dev Cell. 2003;4:481-495. (Pubitemid 36437556)
12. Cao R, Yang Y. E(Z)/EZH2-mediated methylation of lysine 27 in histone H3 Curr Opin Genet Dev. 2004;14:155-164.
13. Straussman R, Nejman D, Cedar H, et al. Developmental programming of CpG island methylation profiles in the human genome. Nat Struct Mol Biol. 2009;19 [Epub ahead of print].
14. Lee TI, Jenner RG, Boyer LA, et al. Control of developmental regulators by polycomb in human embryonic stem cells. Cell. 2006;125:301-313. (Pubitemid 44313811)
15. Bracken AP, Dietrich N, Helin K, et al. Genome-wide mwppin of polycomb genes unravels their roles in cell fate transitions. Genes Dev. 2006;20:1123-1136.
16. Abdulkader I, Sánchez L, Fraga M, et al. Cell-cycle-associated markers and clinical outcome in human epithelial cancers: a tissue microarray study. Oncol Rep. 2005;14:1527-1531.
17. Fraga MF, Ballestar E, Esteller M, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37: 391-400.
18. Lande-Diner L, Cedar H. Silence of the genes- mechanisms of long-term repression. Nat Rev Genet. 2005;6:648-654. (Pubitemid 41044302)
19. Jones PA, Baylin S. The fundamental role of epigenetics in cancer. Nat Rev Genet. 2002;3:415-428.
20. Veigl ML, Kasturi L, Markowitz SD, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing. Proc Natl Acad Sci. 1998;95:8698-8702.
21. American Cancer Society. Cancer facts and figures. Atlanta, GA: The Society. 2007.
22. Greenlee RT, Hill-Harmon MB, Thun M, et al. Cancer statistics, 2001 CA Cancer J Clin. 2001;51:15-36. (Pubitemid 32166444)
23. Meyer T, Rustin GJ. Role of tumor markers in monitoring epithelial ovarian cancer. BR J Cancer. 2000;82:1535-1538. (Pubitemid 30204358)
24. Welsh JB, Zarrinkar PP, Hampton GM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA. 2001; 98:1176-1181. (Pubitemid 32121206)
25. Ahluwalia A, Yan P, Nephew KP, et al. DNA methylation and ovarian cancer: Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol. 2001;82:261-268. (Pubitemid 32730601)
26. Strathdee G, Appleton K, Brown R, et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol. 2001;158: 1121-1127. (Pubitemid 32221804)
27. Tam KF, LiuVW, Ngan HY, et al. Methylation profile in benign, borderline and malignant ovarian tumors. J Cancer Res Clin Oncol. 2007;133:331-341. (Pubitemid 46723501)
28. Braga EA, Loginov VI, Kiselev LL, et al. Activation of RHOA gene transcription in epithelial tumors may be caused by gene amplification and/or demethylation of its promotor region. Mol Biol (Mosk). 2006;40:865-877.
29. Yang HJ, Liu VW, Ngan HY, et al. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer. 2006;6:212.
30. Czekierdowski A, Czekierdowska S, Kotarski J, et al. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett. 2006;27:381-386. (Pubitemid 44390076)
31. Wiley A, Katsaros D, Yu H, et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer. 2006;107:299-308. (Pubitemid 44036559)
32. Kwong J, Lee JY, Mok SC, et al. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia. 2006;107:268-278.